Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995:208:111-7.
doi: 10.3109/00365529509107771.

Early clinical experience with a hybrid bioartificial liver

A A Demetriou  1 , J Rozga, L Podesta, E Lepage, E Morsiani, A D Moscioni, A Hoffman, M McGrath, L Kong, H Rosen, et al.
Affiliations

Early clinical experience with a hybrid bioartificial liver

A A Demetriou et al. Scand J Gastroenterol Suppl. 1995.

Abstract

Background: Severe liver failure is associated with high mortality. Orthotopic liver transplantation (OLT) is the only effective therapeutic modality; there is a need for a 'bridge' system to support patients until an organ becomes available.

Methods: A bioartificial liver (BAL) was used to treat 10 patients with severe liver failure. A plasmapheresis system was used to pump patient plasma through a module with porcine hepatocytes. Each treatment lasted 6-7 h.

Results: All patients tolerated the procedure(s) well. Eight patients underwent OLT following BAL treatment(s). There were two late deaths after recovery from liver failure. Five patients with increased intracranial pressure (ICP) and decerebration had ICP normalization, increased cerebral perfusion pressure and full neurologic recovery after OLT. There was improvement in the level of encephalopathy and a significant decrease in serum ammonia after BAL treatment(s).

Conclusions: BAL treatment is safe and beneficial and can be successfully used as a 'bridge' to transplantation.

PubMed Disclaimer

Publication types

LinkOut - more resources